FindTrial
Sign In

Role of Haloperidol and Olanzapine in the treatment of Delirium

Comparision of efficacy of Haloperidol and Olanzapine in the treatment of Delirium

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/10/007331
Enrollment
100
Registered
2016-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Delirium

Interventions

Intervention1: Haloperidol: 1-4 mg/day, orally or by nasogastric tube, 1-2 divided doses for 3.57 days (Mean duration) Control Intervention1: Olanzapine: 2.5-10mg/day, orally or by nasogastric tube, 1

Sponsors

Government Medical College Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age of patients 18-75 years. 2) Patient should be verbally responsive. 3) Patients or caregiver must give written consent for the study

Exclusion criteria

Exclusion criteria: 1) Mechanically ventilated or mute patients. 2) Patients of alcohol withdrawal delirium. 3) Patients having history of dementia. 4) Patients who had already been injected with antipsychotics in the emergency room or intensive care unit. 5) Patients having hypersensitivity reaction to haloperidol or olanzapine in past.

Design outcomes

Primary

MeasureTime frame
1. Confusion Assessment Method (CAM) 2. Memorial Delirium Assessment Scale (MDAS) 3. Simpson-Angus Scale (SAS) Timepoint: Every 24 hours till resolution of delirium—

Secondary

MeasureTime frame
1. Confusion Assessment Method (CAM) 2. Memorial Delirium Assessment Scale (MDAS) 3. Simpson-Angus Scale (SAS) Timepoint: Every 24 hours till the resolution of Delirium—

Countries

India

Contacts

Public ContactDrPriti Arun

Government Medical College Hospital

ajeetsidana@hotmail.com9646121614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026